Darunavir
Title: Darunavir
CAS Registry Number: 206361-99-1
CAS Name: [(1S,2R)-3-[[(4-Aminophenyl)sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]carbamic acid (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
Additional Names: (1S,2R,3¢R,3¢aS,6¢aR)-[3¢-hexahydrofuro[2,3-b]furanyl-[3-(4-aminobenzenesulfonyl)isobutylamino]-1-benzyl-2-hydroxypropyl]carbamate
Manufacturers' Codes: TMC-114; UIC-94017
Molecular Formula: C27H37N3O7S
Molecular Weight: 547.66
Percent Composition: C 59.21%, H 6.81%, N 7.67%, O 20.45%, S 5.85%
Literature References: Second generation HIV-1 protease inhibitor; structurally similar to amprenavir, q.v. Prepn: A. K. Ghosh et al., Bioorg. Med. Chem. Lett. 8, 687 (1998); idem et al., J. Org. Chem. 69, 7822 (2004). See also: J. W. Erickson, S. V. Gulnik, WO 9967417 (1999 to U.S. Dept. Health Human Serv.); J. W. Erickson et al., US 05158713 (2005 to Univ. Illinois). In vitro activity vs multidrug resistant HIV isolates: Y. Koh et al., Antimicrob. Agents Chemother. 47, 3123 (2003). Crystal structures of complex with protease variants: Y. Tie et al., J. Mol. Biol. 338, 341 (2004). Structure activity study and pharmacokinetic analysis: D. L. N. G. Surleraux et al., J. Med. Chem. 48, 1813 (2005). Review of pharmacology and clinical experience: A. C. Shurtleff, Curr. Opin. Invest. Drugs 5, 879-886 (2004). Clinical evaluation of combination with ritonavir: K. Arastéh et al., AIDS 19, 943 (2005).
Properties: White amorphous solid, mp 74° (dec).
Melting point: mp 74° (dec)
Therap-Cat: Antiviral.
Keywords: Antiviral; Peptidomimetics; HIV Protease Inhibitor.

Others monographs:
AntheridiolKistrinCefclidinOzone
N-MethylmyosmineGuanethidineCiramadolHalcinonide
DomitrobanSodium FormaldehydesulfoxylateMDMADifloxacin
ChlordiazepoxideGlutathioneAcetylcysteineFlesinoxan
©2016 DrugLead US FDA&EMEA